Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

NCT02593539 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Activated PI3K-delta Syndrome

Interventions

DRUG: Nemiralisib

Sponsor

GlaxoSmithKline